Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, ultraviolet light did not significantly enhance or worsen hair growth induced by topical minoxidil in men with male pattern baldness.

Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.

This study found that a 6-month supplementation with omega 3, omega 6, and antioxidants significantly improved hair density and reduced hair loss in women with female pattern hair loss.

This study observed that a CBD-rich topical cannabis extract may increase hair count in patients with androgenetic alopecia when applied daily, but the effect is concentration-dependent and requires further research to establish safety and efficacy.

In this study, trichoscopic features aiding differential diagnosis of alopecia in Korean patients were found to be similar to those in Caucasians, but pigment pattern frequencies differed due to racial characteristics.

This study concluded that in female pattern hair loss patients, CGF and i-PRF treatments were more effective than PRP in increasing target area hair count, with i-PRF having the lowest adverse event rate.

This study found that intra-cochlear administration of z-VAD-FMK for 7 days after gunshot noise trauma in guinea pigs accelerated hearing recovery and preserved hair cell survival.

This article discusses the various skin side effects associated with targeted cancer therapies like tyrosine kinase inhibitors and EGF-R inhibitors but provides no new clinical findings.

Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.

Minoxidil effectively regrows hair in male pattern baldness.

This study found that a 2% topical minoxidil solution was significantly more effective than a placebo in promoting hair growth in women with androgenetic alopecia over 32 weeks.

This article reviews the potential of topical minoxidil to cosmetically thicken hair in some individuals with male pattern hair loss, but it reports no new clinical results.

This study found that 2% minoxidil led to moderate to dense hair growth in 80% of Middle-Eastern men treated for 48 weeks with early androgenic alopecia.

This study found that the new minoxidil formulation, DC0120, was noninferior to the marketed product ALOSTIL® in promoting hair growth for men with androgenetic alopecia over 16 weeks.

This piece describes a study designed to quantify hair density in the frontoparietal area of women without self-reported androgenetic alopecia, but it reports no results.

This study found that 2 percent topical minoxidil significantly increased nonvellus hair count and showed moderate regrowth compared to placebo in women with mild to moderate androgenetic alopecia, although participants did not notice the difference.

In this study, a standardized 7.5% herbal extract significantly increased hair growth in men with androgenetic alopecia compared to a placebo over a 48-week period.

This review examines the efficacy and safety of using minoxidil at concentrations greater than 5% for androgenetic alopecia but reports no new clinical results, emphasizing a need for further research.

This study found that 2% minoxidil solution significantly increased nonvellus hair count in men with male pattern baldness compared to placebo during a 48-week trial.

In this study, viprostol was not effective in promoting hair growth for men with androgenetic alopecia over a 24-week period.

This study found that topical minoxidil is more effective than placebo in promoting hair growth in androgenetic alopecia, although cosmetically acceptable results occur only in a subset of patients.

This study found significant hair regrowth in male pattern baldness using 2% and 3% topical minoxidil solutions compared to placebo over a 4-month period.

This study found that a bleach bath treatment with 0.005% HOCI reduced the expression of certain serine proteases in cultured keratinocytes and lowered skin pH in atopic dermatitis patients, potentially improving symptoms by modulating the NF-kB pathway.

In this study, participants with androgenetic alopecia who used an LED helmet emitting red and green light experienced significant improvements in hair growth measures, with red light showing superior results in increasing hair diameter and reducing vellus hair density over 6 months.

In this study, the researchers found that the topical generic 5% new minoxidil foam is as effective and safe as the 5% Rogaine® foam in increasing hair density and diameter in men with androgenetic alopecia over 24 weeks.

Young men with male pattern baldness lose hair density over time without treatment.

In this randomized study, ViviScal® significantly outperformed a fish extract in increasing non-vellus hair count and achieving clinical and histological improvement in young males with hereditary androgenic alopecia.

This study found that 2% minoxidil solution significantly increased non-vellus hair counts and regrowth rates compared to placebo in men with early androgenic alopecia, suggesting it is an effective treatment.

Keith Kaufman reported promising results on treating male-pattern baldness with oral finasteride at the World Congress of Dermatology.

This study reported that two male patients with diffuse unpatterned alopecia exhibited donor-area involvement in both the vertex and occiput, challenging the assumption of occipital stability for hair transplantation, and showed partial improvement following treatment with oral finasteride and topical minoxidil.